Sanofi (NASDAQ:SNY) Shares Sold by B. Riley Wealth Advisors Inc.

B. Riley Wealth Advisors Inc. reduced its holdings in shares of Sanofi (NASDAQ:SNY) by 20.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,722 shares of the company’s stock after selling 4,203 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in Sanofi were worth $811,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in SNY. Vestal Point Capital LP acquired a new position in shares of Sanofi during the fourth quarter valued at about $14,919,000. Dynamic Advisor Solutions LLC raised its holdings in shares of Sanofi by 39.2% in the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock worth $2,780,000 after buying an additional 16,117 shares during the last quarter. Manning & Napier Advisors LLC acquired a new stake in shares of Sanofi during the second quarter worth $13,725,000. Mount Yale Investment Advisors LLC grew its holdings in shares of Sanofi by 44.3% during the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after buying an additional 12,806 shares during the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Sanofi by 18.9% during the first quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock valued at $9,216,000 after buying an additional 30,115 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Down 0.1 %

Sanofi stock opened at $55.47 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The stock has a market capitalization of $140.49 billion, a PE ratio of 27.87, a price-to-earnings-growth ratio of 1.62 and a beta of 0.60. The business has a 50 day simple moving average of $55.46 and a 200-day simple moving average of $51.04. Sanofi has a 12 month low of $42.63 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.95 EPS. On average, analysts anticipate that Sanofi will post 4.26 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on SNY. StockNews.com raised Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Argus lifted their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.